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Background: The number of routine care patient examinations with 68Ga radiopharmaceuticals is still relatively
limited, probably caused by the presumed need for large investments in hot cells, automated synthesis modules,
laboratory equipment and validation efforts. Our aim was to set up the preparation of 68Ga-DOTA-NOC in
compliance with all current European Union-Good Manufacturing Practices (EU-GMP), current Good Radiopharmacy
Practice (cGRPP) and European Pharmacopoeia (Ph. Eur.) guidance but without the availability of a hot cell and gas
chromatography (GC), high-performance liquid chromatography (HPLC) and atomic absorption spectrometry (AAS)
equipment.
Methods: A risk-based approach was applied to align preparation conditions with applicable regulations, together
with a validation of a thin-layer chromatography (ITLC) method to replace HPLC as modality for examining
radiochemical purity.
Results: Using an internally shielded labelling module for manual operation, a 68Ga-DOTA-NOC labelling
procedure was set up that meets all applicable Ph. Eur. specifications. The applied ITLC method showed very
good correlation with HPLC results (r = 0.961) and was able to detect relevant deviations in radiolabelling
procedures. All identified quality assurance aspects were made compliant with EU-GMP and cGRPP guidance.
Conclusions: We consider the described configuration and validation approach feasible for many conventional
small-scale radiopharmacies, something that could help to increase the availability of 68Ga radiopharmaceuticals to a
large number of patients.
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Within the field of nuclear medicine, there has been an
interest in the clinical applications of the 68Ge/68Ga gener-
ator for several decades. Already in 1960, Gleason de-
scribed the ‘positron cow’, which at that time was used for
the compounding of 68Ga-EDTA for the imaging of brain
tumours [1]. With a physical half life of 68 min, availability
independent of a cyclotron and excellent binding charac-
teristics to chelators such as DOTA 68Ga has excellent
properties for routine clinical application. The most widely
implemented application of 68Ga at present is the imaging* Correspondence: r.vis@antoniusziekenhuis.nl
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in any medium, provided the original work is pof somatostatin receptor positive tumours. This applica-
tion, most specifically in the imaging of neuro-endocrine
tumours (NET), has taken off with the development
of 68Ga-DOTA-TOC, 68Ga-DOTA-NOC and 68Ga-DOTA-
TATE, all analogues of octreotide with differing affinity
for the somatostatin receptor subtypes 2, 3 and 5 [2-5].
The 2010 European Association of Nuclear Medicine
(EANM) guidelines for PET/CT tumour imaging with
68Ga-DOTA-conjugated peptides states that positron
emission tomography (PET) with 68Ga-DOTA-TOC,
68Ga-DOTA-NOC and 68Ga-DOTA-TATE has brought
about dramatic improvements in spatial resolution in the
imaging of NET as compared to conventional imaging
with SPECT tracers [6].pen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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seems that 68Ga radiopharmaceuticals are finally ‘breaking
through’. The number of publications concerning 68Ga ra-
diopharmaceuticals has increased drastically during the
past years: the number of 68Ga-related scientific articles
published in 2011 to 2012 accounts for over 45% of all
publications since 1956 [7]. Furthermore, several recent
publications of the highly promising new tracer, 68Ga-
labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-
HBED-CC), for the imaging of prostate cancer have come
available, thereby significantly expanding the clinical
possibilities of 68Ga radiopharmaceuticals within on-
cology outside of the relatively small number of patients
with NET [8,9].
Despite the recent advances, the availability of 68Ga ra-
diopharmaceuticals to patients is still relatively limited.
An estimated 10,000 scans are being performed yearly in
Europe at about 100 centres using 68Ga-labelled somato-
statin analogues; for the USA, only 2 university sites have
begun to undertake human studies [10]. In the Netherlands,
68Ga radiopharmaceuticals for routine clinical use are cur-
rently available in three hospitals only, two of which are
university medical centres. Several factors for this past-
hampered clinical introduction of 68Ga radiopharmaceuticals
can be identified and include a scarcity of 68Ga generators,
absence of 68Ga radiopharmaceuticals with a marketing
authorisation (absence of radiopharmaceutical cold kits)
and lack of PET radiopharmaceutical regulations [7]. Pres-
ently, several Good Manufacturing Practices (GMP)-grade
generators are commercially available, as well as different
(semi-)automated synthesis modules [7,11]. In 2014, the
first generator received a marketing authorisation in the
European Union (EU). Moreover, with the publication of
the European Pharmacopoeia (Ph. Eur.) monographs on
68Ga-chloride and 68Ga-edotreotide (DOTA-TOC) injec-
tion and the EANM guideline on the small-scale ‘in-house’
preparation of radiopharmaceuticals which are not kit
procedures (cGRPP) and the existing EU-GMP annexes’
very specific guidance and quality requirements are cur-
rently provided [12-15]. Although these developments
have reduced the number of barriers to implement 68Ga
radiolabelling for routine clinical use, several still remain.
The major barriers involve the required investment in hot
cells, a synthesis module and quality control equipment
(e.g. gas chromatography (GC), high-performance liquid
chromatography (HPLC) and atomic absorption spec-
trometry (AAS) suitable for and dedicated to radiopharma-
ceuticals) and validation efforts. These prerequisites are
more easily met in well-equipped (often university hospital)
radiopharmacy departments but less often in conventional
small-scale radiopharmacies. This situation could hamper
the widespread utilization of 68Ga-radiopharmaceuticals in
the future, thereby denying large numbers of patients access
to state-of-the-art nuclear medicine diagnostics. Our aimwas to set up the preparation of 68Ga-DOTA-NOC in com-
pliance with all current EU-GMP, cGRPP and Ph. Eur.
guidance but without the availability of a hot cell and GC,
HPLC and AAS equipment.
Methods
Facilities and equipment
The radiopharmacy department of the St Antonius Hospital
(850-bed teaching hospital), Nieuwegein, The Netherlands,
situates two cleanrooms, one with GMP grade D and one
with GMP grade C air quality. Within the latter clean-
room, one GMP grade A workstation (lead-shielded uni-
directional laminar airflow workbench (LAFW)) is placed.
For labelling of 68Ga-radiopharmaceuticals, a labelling
module for manual operation and a GMP grade 925 MBq
68Ge/68Ga generator were obtained from ITG (Gärching/
Munich, Germany). The labelling module (Figure 1) is in-
ternally lead-shielded and situated on a standard workbench
in the background environment. Placing the labelling mod-
ule in a GMP grade C background is in accordance with the
Annex 3 GMP and cGRPP guideline for on-line sterile filtra-
tion in a closed system under the condition that the aseptic
assembly of all components down-stream of the filter is
performed in a GMP grade A environment [14,15].
The ITG labelling module holds an internal block
heater wherein a disposable reaction vessel (part of the
disposable cassette) is placed. The 68Ge/68Ga generator
is situated in the bottom section of the module, and a
disposable cassette system (per batch) is placed in the
top section. After installation of the cassette system, the
(lead-shielded) upper lid of the module is closed, thereby
providing lead shielding of both the reactor vessel and
all tubing. All solutions needed during the labelling can
be introduced by means of plastic syringes through small
openings in the upper lid or in front of the module. Be-
cause the labelling module is designed for manual non-
electrical operation, software validation according to the
GAMP-5 methodology was not applicable [16]. Further-
more, no specific cleaning validation was applicable be-
cause all materials that might contact the product are
for single use only.
All radioactivity measurements are performed with a
standard ionization chamber (VIK-202; Comecer, Joure,
The Netherlands).
Preparation and process controls
For radiolabelling, the ITG GMP grade 68Ga radiolabelling
kit and single-use sterile cassette were used (ABX Advanced
Biochemical Compounds, Radeberg, Germany). GMP-grade
DOTA-NOC acetate in 60 μg vials was obtained from
ABX (Radeberg, Germany). ABX was approved as a sup-
plier in conformance with our quality management system
based on their GMP manufacturing authorisation and a
supplier audit.
Figure 1 The labelling module.
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Prior to every labelling, the generator is rinsed with 0.05 M
hydrochloric acid unless the generator has been eluted
within the previous 24 h. Dependent on the period from
last elution (24 to 72 or >72 h) the rinsing volume is 10 or
20 ml, respectively. The rinsing solution is transferred to a
waste vial directly. For every labelling procedure, a sterile
single-use cassette is installed in the labelling module. The
C18 purification cartridge is conditioned with 2 ml 70%
(V/V) ethanol, purged with 1 ml air and subsequently
rinsed with 5 ml sodium chloride (NaCl) 0.9%. The assem-
bly of the sterile final product vial with needle and 0.2 μm
product filter and venting needle/filter is performed
under aseptic conditions in the LAFW (grade A environ-
ment) and transferred to the grade C environment for
assembly to the cassette. The connection between the
cassette and the final product vial is upstream of the
sterilizing filter.
For the labelling procedure, 60 μg DOTA-NOC acetate
was dissolved in 150 μl of 0.25 M sodium acetate buffer.
After switching on the block heater within the labelling
module at a fixed time, a volume of 100 μl DOTA-NOC
(40 μg) is added with a calibrated microlitre pipette (range
10 to 100 μl) to a volume of 1 ml 0.25 M sodium acetate
buffer and subsequently injected in the reaction vessel.
After a heating time of 5 min, direct elution of the
68Ge/68Ga generator is performed with 4 ml 0.05 M
hydrochloric acid into the reaction vessel. Labelling
takes place at 90°C to 95°C for 10 min. Subsequently,
the labelling mixture is transferred to the waste vial
through the C18 purification column and rinsed with
5 ml 0.9% NaCl. In the final step, the C18 purification
column is eluted with 1 ml 60% (V/V) ethanol and rinsed
with 5 ml 0.9% NaCl through the on-line 0.2 μm filter into
the product vial.Routine in process controls
Labelling is performed according to a paper worksheet
by two operators, and all process steps are signed off by
both operators. After installation of the cassette, a leak
test is performed with 0.9% NaCl to verify that no leak-
age occurs. Temperature settings are signed off as well
as the temperature readings at set time intervals during
the labelling. The percentage of waste activity is docu-
mented for information purposes only, although the
measure can be indicative of a labelling failure (unbound
68Ga).
Quality control of the 68Ge/68Ga generator
Considering the non-metallic matrix of the ITG 68Ge/
68Ga generator, a validation study was performed to assess
the necessity for routine testing for iron and zinc. We
therefore took eluate samples after (1) 1 week after last
elution of the generator, (2) 1 day after last elution of the
generator and (3) 3 h after last elution of the generator.
The iron and zinc contents were determined by means
of inductively coupled plasma (ICP) by the Department
Radiation, Science and Technology (RST), section Radiation
and Isotopes in Health (RIH) at the Delft University of
Technology, the Netherlands.
For the eluate from the generator, there is no require-
ment of sterility, but there is a requirement for bacterial
endotoxins of less than 175 IU/V with V the maximum
volume to be used for the preparation of a single patient
dose [12]. Since we elute the 68Ge/68Ga generator in the
grade C environment and use non-sterile hydrochloric
acid, we performed a validation study to evaluate the intro-
duction of bioburden and endotoxins due to non-aseptic
generator elution conditions. For worst-case purposes, we
used 0.05 M hydrochloric acid that was of ultrapure, la-
boratory grade that was not tested for bioburden or
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endotoxins were obtained (1) after leaving the generator
stagnant for 1 month and (2) 2 h after rinsing with 30 ml
hydrochloric acid. The endotoxin content was determined
by means of a kinetic LAL assay (Kinetic-QCL®, Lonza,
Walkersville, MD, USA).
Another quality parameter for 68Ge/68Ga generators is
the breakthrough of the long-lived parent radionuclide
68Ge (impurity A in the monograph for 68Ga chloride and
impurity C in the monograph for 68Ga-edotreotide) and
its content in the final radiopharmaceutical preparation.
Therefore, upon receipt of the 68Ge/68Ga generator, we
performed a 68Ge breakthrough test of both eluate and la-
belled 68Ga-DOTA-NOC according to the Ph. Eur.
Based on the acquired results, an overall evaluation was
made to assess the applicability and control methods of
all parameters defined in the Ph. Eur. monograph on
68Ga-chloride.
Quality control of 68Ga-DOTA-NOC
Since no HPLC apparatus is available for radiopharma-
ceuticals at the St Antonius Hospital, initial verification
of the labelling procedure was performed at ITG and in-
volved the preparation of three validation batches in a
time course of 2 days. Quality control was performed
with HPLC in accordance with the Ph. Eur. monograph
directly after labelling and for one batch after a max-
imum of 5.5 h of storage at ambient temperature in ei-
ther a glass vial or a polypropylene syringe [13]. Parallel
with one batch, a cross-validation study was performed
to verify the suitability of two different thin-layer chroma-
tography (ITLC) methods for unbound 68Ga (impurity B)
to replace the HPLC method from the Ph. Eur. mono-
graph. Fresh 68Ga-DOTA-NOC was ‘spiked’ with impurity
B (fresh eluate) to simulate labelling efficiencies in the
range of 85% to 100%. All batches were analyzed with
three methods to determine the activity of 68Ga-DOTA-
NOC as percentage of total activity: (1) HPLC, (2) ITLC
method 1 and (3) ITLC method 2. For ITLC method 1,
Merck Millipore TLC silica gel 60 F254 aluminium sheets
(Billerica, MA, USA) as stationary phase, 0.1 M citric acid
buffer at pH 4 to 5 as mobile phase with radiodetection
after cutting the sheets in half and for ITLC method 2,
Varian ITLC-SG as stationary phase, 0.1 M citric acid buf-
fer at pH 4 to 5 as mobile phase with radiodetection after
cutting the sheets in half were used. Spearman’s test for
correlations was applied to HPLC versus ITLC method 1
and HPLC versus ITLC method 2 using IBM SPSS 22.0
Statistics (Statistical Package for the Social Sciences; IBM,
Armonk, New York, NY, USA).
After the initial cross-validation study at ITG, the cor-
rect performance of the ITLC method for impurity B
was confirmed on-site at the St Antonius Hospital. At St
Antonius, radiochromatogram scanning was performedwith a VCS-203 chromatography scanner (Comecer,
Joure, the Netherlands). The ITLC method for impurity
A was performed in conformance with the applicable
Ph. Eur. monograph at all times.
Besides the test for the potential introduction of bio-
burden and endotoxins from the generator, a validation
study was performed to assess the total bioburden and
possible introduction of bacterial endotoxins from non-
sterile DOTA-NOC acetate, the 68Ga radiolabelling kit
and C18 purification cartridge. To do so, three full mock
labellings were performed excluding heating to prevent
the risk of bioburden reduction through heating at 90°C
to 95°C. The endotoxin content was determined as de-
scribed before.
The filter integrity after the final sterile filtration was
assessed by conducting a filter integrity test using a Merck
Millipore filter tester (SLTEST000, Merck Millipore Co.,
Billerica, MA, USA). After rinsing the filter with 10 ml
water for injections, the bubble point is determined with a
requirement of a minimum of 3,450 mbar/50 psi accord-
ing to the Merck Millipore requirements. In more detail, a
closed system is constructed with a sterile 50 ml Luer-lock
syringe connected to the Merck Millipore filter tester,
which is again connected to the filter unit. From the
filter unit, a needle is placed in a 100-ml vial contain-
ing water for injections in which the bubble point is
determined. This method is based on the evaluation
provided by Hayashi et al. [17].
To assess the overall appropriateness of the aseptic
process, three media fills were performed by direct inocu-
lation of tryptic soy broth medium (TSB, bioTRADING
Benelux B.V., Mijdrecht, the Netherlands). The aseptic
assembly of all components down-stream of the filter
was performed in the GMP grade A environment and
subsequently TSB medium that has been air-exposed
to the grade C environment was filtered. The filtered
TSB medium was subsequently incubated at 30°C for
14 days.
Based on the results obtained, an overall evaluation was
made to assess the applicability and control methods of
all parameters defined in the Ph. Eur. monograph on
68Ga-edotreotide. The final labelling procedure was sub-
sequently tested through the preparation of three valid-
ation batches on three separate days with quality control
directly after labelling and for one batch after storage in a
plastic syringe for 1.5 h as well.
Radiation safety
All radiopharmacy technicians were trained in radiation
protection and wear personal thermoluminescence do-
simeters (TLDs) (NRG, Petten, the Netherlands) which
are evaluated monthly. To assess the body dose during a
labelling, a study was performed with measurement of
total dose during rinsing of the 68Ge/68Ga generator and
Table 1 Selected parameters from the Ph. Eur. monograph
on 68Ga-chloride and how they are controlled
Parameter Specification Method
Iron Maximum 10 μg/GBq Quality by design: risk-based
approach eliminated need
for routine test
Zinc Maximum 10 μg/GBq Quality by design: risk-based
approach eliminated need
for routine test
Bacterial
endotoxins
Less than 175 IU/V to be
used for the preparation
of a single patient dose
Quality by design: risk-based
approach eliminated need
for routine test
Impurity A ≤0.001% Ionization chamber: performed
at time of acceptance of generator
Table 2 Results of validation of HPLC versus ITLC
(presented as 100% minus impurity B)
Sample Percentage of
Ga-68-DOTA-
NOC (HPLC)
Percentage of
Ga-68-DOTA-
NOC (ITLC 1)
Percentage of
Ga-68-DOTA-
NOC (ITLC 2)
Validation 1 98.2 98.3 98.5
Validation 2 98.1 98.0 98.3
Validation 3 98.7 99.2 98.5
Spike 5% 93.7 94.5 91.4
Spike 10% 89.5 89.9 89.6
Spike 15% 84.8 85.2 87.6
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body of the radiopharmacy technician. For this study
electronic personal dosimeters were used (ThermoFisher
Scientific Inc., Waltham, MA, USA).
Results and discussion
Quality control of the 68Ge/68Ga generator
The assay for iron and zinc in the generator eluate sam-
ples after (1) 1 week after last elution of the generator, (2)
1 day after last elution of the generator and (3) 3 h after
last elution of the generator resulted in levels of iron of
1.8, 3.7 and 0.91 μg/GBq respectively and levels of zinc of
10, 1.2 and 1.8 μg/GBq respectively. This means that the
results were in conformance with the Ph. Eur. require-
ment of a maximum of 10 μg/GBq for all samples al-
though the zinc level in the eluate after resting of the
generator for 1 week was at the Ph. Eur. maximum. These
findings are in accordance with the decay scheme of 68Ga
yielding zinc but also confirm that the non-metallic matrix
of the generator in itself is no source of iron or zinc. Con-
sidering this, the introduction of a standard rinsing pro-
cedure of the generator prior to eluting for labelling seems
sufficient and will prevent the need for AAS equipment
for routine testing of iron and zinc.
After the 68Ge/68Ga generator had been left stag-
nant for 1 month, we observed a bioburden of 300 col-
ony forming units (cfu)/ml in the eluate, which was
reduced to <10 cfu/ml (no growth) after the standard rins-
ing procedure. The endotoxin content of both elutions
were <0.250 IU/ml and therefore much lower than the re-
quirements of 175 IU/V ml. The bioburden and endotoxin
levels of the 0.05 M hydrochloric acid are controlled and
specified on the certificate of analysis. We consider the
verification of this certificate sufficient and therefore do
not perform a routine assay for bioburden or bacterial en-
dotoxins on the 68Ga eluate.
The 68Ge breakthrough test of the eluate showed a
breakthrough of 0.0009% which is below the limit from the
Ph. Eur monograph of ≤0.001%. The 68Ge breakthrough in
the final product was equal to zero in the batch tested and
confirms the effectiveness of the post-labelling purification
step by C18 cartridge. In our opinion, the only clinically
relevant content of 68Ge is in the final product and not in
the eluate. Also considering that the procedure for assess-
ment of 68Ge breakthrough in the final product is not feas-
ible in routine practice (measurement after full decay of
68Ga), a 68Ge breakthrough test at acceptance of every new
generator could be sufficient.
In summary, the validation work on the quality control
of the 68Ge/68Ga generator in our specific configuration
showed that based on a risk-based approach and the re-
sults from the validation studies, the tests on iron, zinc,
68Ge-breakthrough and endotoxins can be limited to an
initial qualification of the generator only (see Table 1).Quality control of 68Ga-DOTA-NOC
The results of the HPLC versus ITLC validation are
summarized in Table 2. The cross-validation work for
impurity B showed good correlation between HPLC and
the two ITLC methods (ITLC method 1: r = 0.999 and
ITLC method 2: r = 0.961, see Figure 2). Although the
correlation between HPLC and ITLC method 1 shows
somewhat better, we consider method 2 more appropriate
given the much shorter run time for the mobile phase over
the stationary phase. This shortens the time needed for
quality control between preparation and administration to
the patient. Based on the validation results obtained, we
concluded that ITLC method 2 can be considered appro-
priate to eliminate the need for HPLC to assess impurity B
from the Ph. Eur. monograph.
Another test from the Ph. Eur. monograph for 68Ga-
edotreotide injection is a HPLC method for a test on
edotreotide (maximum 50 μg per maximum dose) [13].
Because in our labelling procedure only 40 μg DOTA-
NOC is used, this test can be considered not applicable.
The correct amount is assured by applying vials with a
maximum content of 60 μg and verifying the correct re-
constitution and drawing of the required amount by two
radiopharmacy technicians. These steps are recorded on
to the paper worksheet.
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Figure 2 Correlation between HPLC and the two ITLC methods.
Vis et al. EJNMMI Research  (2015) 5:27 Page 6 of 7Also the assessment of total ethanol content and im-
purity D (HEPES) in the final dose 68Ga-DOTA-NOC
appeared not applicable after a risk evaluation. The total
amount of ethanol introduced in the final product is
0.47 g or 10% (V/V) which is far below the absolute max-
imum of 2.5 g per administration and conform the re-
quirement of 10% (V/V). This calculation prevents the
need for routine GC analysis for ethanol content. The
ITLC test on impurity D is not required because no
HEPES buffer is used in the preparation process.
For all mock labellings, we observed a bioburden
of <10 cfu/ml (no growth) and endotoxin content of
<0.125 IU/ml. This endotoxin content is far below theTable 3 Selected parameters from the Ph. Eur. monograph
on 68Ga-edotreotide and how they are controlled
Parameter Specification Method
Identity DOTA-NOC DOTA-NOC Acceptance of raw material
Content: 68Ga 90 – 110% of the
declared 68Ga
radioactivity
Ionization chambera
Content: DOTA-NOC Maximum 50 μg Quality by design: pre-filled vials
with amount needed together
with double check in
batch recorda
Appearance Clear, colourless
solution
Visual inspectiona
pH 4.0 to 8.0 pH indicator stripa
Ethanol Maximum 10%
(V/V)/maximum
2.5 g per dose
Quality by design: risk-based
approach eliminated need
for routine test
Sterility Sterile; bubble
point >3,450 mbar
Validation of aseptic process
together with filter integrity testa
Bacterial endotoxins Less than 175 IU
per dose
Quality by design: risk-based
approach eliminated need
for routine test
Impurity A ≤3% ITLCa
Impurity B ≤2% Validated ITLC method to
replace HPLCa
Impurity C ≤0.001% Ionization chamber; assessed at
time of acceptance of generator
aParameter with corresponding method that is performed after every
preparation of 68Ga-DOTA-NOC.threshold of 175 IU/V ml (see before). When considering
these results together with the specifications of the steril-
izing filter used, we conclude that the pre filter biobur-
den is far below the maximum capacity of the filter. The
Cathivex® GV filter (Millipore) used for on-line sterile fil-
tration employs the Millipore Durapore® 0.22-μm mem-
brane which is validated to withstand a challenge with
4.0 × 107 of the micro-organism Brevundimonas diminuta.
These numbers are even much higher than the worst-case
bioburden of 300 cfu/ml observed after leaving the 68Ge/
68Ga generator stagnant for 1 month (see before). Based
on this validation work and evaluation, we consider that a
routine analysis of bioburden or bacterial endotoxins is
not warranted except for a successful filter integrity test as
a release criterium. This approach is also supported by the
successful validation of the aseptic process showing no
bacterial growth after incubation of the media in any of
the three simulation experiments. According to the GMP
principles, this aseptic validation will need to be repeated
biannually together with a personal aseptic qualification of
all technicians.
In summary, some tests in the Ph. Eur. monograph on
68Ga-edotreotide can pose a problem in the absence of
GC and HPLC equipment. The validation work on the
quality control of 68Ga-DOTA-NOC in our specific con-
figuration showed that based on a risk-based approach
and the results from validation studies, the tests on
quantity of DOTA-NOC, ethanol content, endotoxin
levels and impurity D need not be performed on a rou-
tine basis. The test for impurity B can be replaced by anTable 4 Results of validation batches (directly after
labelling)
Parameter Validation batches (n = 3)
Appearance Clear, colourless solution
Mean pH (range) 5.0 (5.0)
Filter integrity Pass
Mean impurity A (%) ± SD 0.94 ± 0.54
Mean impurity B (%) ± SD 0.21 ± 0.18
SD, standard deviation.
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specifications and test methods considered applicable to
the labelling procedure presented is provided in Table 3.
Table 4 shows the results from the three validation
batches prepared in our facility prior to the release of the
final labelling procedure for routine clinical use. Finally,
the configuration and validation approach described above
does apply to 68Ga-DOTA-NOC, and many aspects may
require additional validation efforts when labelling other
peptides. Furthermore, any configuration should always
comply with the local quality management system.
Radiation safety
Personal dosimetry with routine TLD monitoring did
not reveal an increase in radiation exposure to the body.
The total personal radioactivity dose during rinsing of
the 68Ge/68Ga generator with 30 ml 0.05 M hydrochloric
acid (originally required after >72 h of no elution) was
found to be 2 μSv. The personal radioactivity dose dur-
ing the subsequent 68Ga radiolabelling procedure ob-
served was 1 μSv. This implies that one rinsing of the
generator followed by a labelling procedure corresponds
to 3 μSv. Unfortunately, we did not assess the finger
dose during drawing of the final product into a syringe
and during administration to the patient. For the specific
purpose of evaluation of possible labelling strategies,
however, this can be considered as less relevant because
drawing into a syringe and administration to a patient
will be required anyhow independent of the labelling
strategy applied.
Conclusions
The described implementation and validation approach
for the preparation of 68Ga-DOTA-NOC is shown to re-
sult in a robust labelling strategy that complies with all
current EU-GMP, cGRPP and Ph. Eur. guidelines and
monographs, but without the need for a hot cell, radio-
chemical HPLC, GC or AAS equipment. It is our strong
belief that with this type of validation approach, the
implementation of 68Ga radiolabelling should be feasible
in much more nuclear medicine facilities than apparent
today. Adopting these practices could aid in increasing
the availability of 68Ga radiopharmaceuticals to a large
number of patients.
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